Acquired drug resistance in mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis

Emerging Infectious Diseases

Volumn 21, Issue 6, 2015, Pages 992-1001

  Kempker, Russell R ^a   Kipiani, Maia ^b   Mirtskhulava, Veriko ^c   Tukvadze, Nestani ^b   Magee, Matthew J ^d   Blumberg, Henry M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Centre for Tuberculosis and Lung Disease   (Georgia)

^c Georgia   (Georgia)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN; KANAMYCIN; OFLOXACIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME; COMORBIDITY; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; MULTIDRUG RESISTANCE; PROGNOSIS; RETROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; COINFECTION; COMORBIDITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84929406848     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2106.141873     Document Type: Article

References (28)

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/2013. Geneva: The Organization; 2013.
2. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva: The Organization; 2014.
3. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61. http://dx.doi.org/10.1016/S1473-3099(09)70041-6
4. Holtz TH. XDR-TB in South Africa: revised definition. PLoS Med. 2007;4:e161. http://dx.doi.org/10.1371/journal.pmed.0040161
5. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2:321-38. http://dx.doi.org/10.1016/S2213-2600(14)70031-1
6. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009; 13:1320-30.
7. Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis. 2012;55: 1600-7. http://dx.doi.org/10.1093/cid/cis748
8. Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis. 2008;47:1126-34. http://dx.doi.org/10.1086/592252
9. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149:123-34. http://dx.doi.org/10.7326/0003-4819-149-2-200807150-00008
10. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6:e1000150. http://dx.doi.org/10.1371/journal.pmed.1000150
11. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049-63. http://dx.doi.org/10.1093/cid/ciu572
12. Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010;182:426-32. http://dx.doi.org/10.1164/rccm.200911-1768OC
13. Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, et al. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012;54:e51-4.http://dx.doi.org/10.1093/cid/cir904
14. Gegia M, Kalandadze I, Kempker RR, Magee MJ, Blumberg HM. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis. 2012;16:e391-6. http://dx.doi.org/10.1016/j.ijid.2011.12.018
15. Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, Blumberg HM, Kempker RR. Significant clinical impact of a rapid molecular diagnostic test (genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1559-66. http://dx.doi.org/10.1093/cid/ciu631
16. Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK, Apsindzelashvili R, et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS ONE. 2012;7:e31563. http://dx.doi.org/10.1371/journal.pone.0031563
17. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev. 2011;24:314-50. http://dx.doi.org/10.1128/CMR.00059-10
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81. http://dx.doi.org/10.1016/j.jbi.2008.08.010
19. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 Update. WHO/HTM/TB/ 20116. 2011. Geneva: The Organization; 2011.
20. Hosmer DW, Lemeshow S, May S. Model development. In: Applied survival analysis: regression modeling of time-to-event data. 2nd ed. Hoboken (NJ): Wiley-Interscience; 2008. p. 132-68.
21. Bonnet M, Pardini M, Meacci F, Orru G, Yesilkaya H, Jarosz T, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS ONE. 2011;6:e23081. http://dx.doi.org/10.1371/journal.pone.0023081
22. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol. 2010;5:96-114. http://dx.doi.org/10.2174/157488410791110797
23. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204:1951-9. http://dx.doi.org/10.1093/infdis/jir658
24. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208:1464-73. http://dx.doi.org/10.1093/infdis/jit352
25. Vashakidze S, Gogishvili S, Nikolaishvili K, Dzidzikashvili N, Tukvadze N, Blumberg HM, et al. Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery. Ann Thorac Surg. 2013;95:1892-8. http://dx.doi.org/10.1016/j.athoracsur.2013.03.067
26. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis. 2012;12:157-66. http://dx.doi.org/10.1016/S1473-3099(11)70244-4
27. Cox HS, Sibilia K, Feuerriegel S, Kalon S, Polonsky J, Khamraev AK, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med. 2008;359:2398-400. http://dx.doi.org/10.1056/NEJMc0805644
28. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013;45:784-90. http://dx.doi.org/10.1038/ng.2656